In summary, our results implicate the IL-1β/CEBPβ/MMP signaling pathway as a major mediator of RCC tumor cell invasion, and this pathway should be considered in the design of preclinical models of RCC to test its target-ability as an anti-metastatic therapy. Here, CEBPB is linked to neoplasm.